Article | January 7, 2022

Key Considerations For The Implementation Of Successful Decentralized Clinical Trials

Source: Kayentis

By Estelle Haenel, Medical Director at Kayentis

Laptop clinical trials iStock-653839742

Many chronic diseases such as invasive cancers, inflammatory disorders, cardiovascular, or central nervous system diseases can have a significant impact on patient mobility as well as hindering the ability of caregivers to accompany patients to clinic visits. Hybrid and decentralized clinical trials can provide these patients the opportunity to participate in a clinical trial or even receive a treatment to which they would otherwise not have access.

Decentralized Clinical Trials (DCTs) are recognized as being an integrated and necessary part of the new clinical trial paradigm and require specific considerations in addition to those for site-based clinical trials.

Specific therapeutic area requirements prevent some clinical trials taking place away from a clinical site. Additionally, the requirements of a particular patient population, protocol design specificities, or regulatory requirements also need to be considered.

To learn more about Kayentis, visit their Clinical Leader page.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader